Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuberitamab vs Cyclosporine in Primary Membranous Nephropathy
NCT07830433Phase 3Not yet recruiting
- Sponsor
- BioRay Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 3 trial of zuberitamab in primary membranous nephropathy (PMN), sponsored by BioRay Pharmaceutical. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zuberitamab
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07830433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830433.